Brokers Issue Forecasts for ACADIA Pharmaceuticals Inc.’s FY2026 Earnings (NASDAQ:ACAD)

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Equities researchers at Leerink Partnrs cut their FY2026 earnings estimates for ACADIA Pharmaceuticals in a report released on Tuesday, April 9th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceutical company will earn $1.42 per share for the year, down from their previous forecast of $2.31. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.63 per share. Leerink Partnrs also issued estimates for ACADIA Pharmaceuticals’ FY2027 earnings at $2.13 EPS and FY2028 earnings at $2.93 EPS.

A number of other research firms have also recently commented on ACAD. Oppenheimer reiterated a “market perform” rating and set a $25.00 price target on shares of ACADIA Pharmaceuticals in a report on Monday, February 5th. TheStreet upgraded shares of ACADIA Pharmaceuticals from a “d” rating to a “c” rating in a report on Tuesday, February 27th. Cantor Fitzgerald reiterated an “overweight” rating and set a $37.00 price target on shares of ACADIA Pharmaceuticals in a report on Wednesday. Morgan Stanley cut their price target on shares of ACADIA Pharmaceuticals from $40.00 to $30.00 and set an “overweight” rating on the stock in a report on Wednesday, March 13th. Finally, JPMorgan Chase & Co. cut their price target on shares of ACADIA Pharmaceuticals from $29.00 to $25.00 and set an “overweight” rating on the stock in a report on Monday, March 25th. Three analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $35.82.

ACADIA Pharmaceuticals Price Performance

ACAD stock opened at $17.14 on Friday. ACADIA Pharmaceuticals has a 1 year low of $16.85 and a 1 year high of $33.99. The firm has a 50-day moving average of $21.70 and a 200 day moving average of $23.91. The company has a market cap of $2.82 billion, a P/E ratio of -45.10 and a beta of 0.37.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its earnings results on Tuesday, February 27th. The biopharmaceutical company reported $0.28 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.04). ACADIA Pharmaceuticals had a negative return on equity of 15.67% and a negative net margin of 8.44%. The firm had revenue of $231.04 million for the quarter, compared to analysts’ expectations of $223.79 million. During the same quarter in the prior year, the company posted ($0.26) earnings per share. The business’s revenue for the quarter was up 69.3% on a year-over-year basis.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Quest Partners LLC purchased a new position in ACADIA Pharmaceuticals in the fourth quarter worth approximately $39,000. KBC Group NV acquired a new stake in ACADIA Pharmaceuticals during the fourth quarter worth approximately $83,000. China Universal Asset Management Co. Ltd. raised its holdings in ACADIA Pharmaceuticals by 97.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 4,202 shares of the biopharmaceutical company’s stock worth $88,000 after purchasing an additional 2,070 shares in the last quarter. State of Wyoming acquired a new stake in ACADIA Pharmaceuticals during the fourth quarter worth approximately $92,000. Finally, Lazard Asset Management LLC raised its holdings in ACADIA Pharmaceuticals by 35.8% during the second quarter. Lazard Asset Management LLC now owns 4,125 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 1,088 shares in the last quarter. Hedge funds and other institutional investors own 96.71% of the company’s stock.

Insider Activity

In other news, insider James Kihara sold 1,790 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $17.87, for a total value of $31,987.30. Following the completion of the transaction, the insider now owns 13,100 shares of the company’s stock, valued at $234,097. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, insider James Kihara sold 1,790 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $17.87, for a total value of $31,987.30. Following the completion of the transaction, the insider now owns 13,100 shares in the company, valued at $234,097. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Stephen Davis sold 5,577 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $24.67, for a total transaction of $137,584.59. Following the completion of the transaction, the chief executive officer now owns 101,890 shares of the company’s stock, valued at approximately $2,513,626.30. The disclosure for this sale can be found here. Over the last quarter, insiders sold 69,383 shares of company stock valued at $1,291,362. 27.50% of the stock is currently owned by company insiders.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.